Elicit Labs

Elicit Labs is an AI research startup focused on automating scientific literature review, founded in 2021.

Reviewed by 7wData
Share Email

On this page

Profile

AI tools that automate the process of finding and summarizing scientific research papers.

Elicit Labs is an AI research startup focused on automating scientific literature review, founded in 2021. The company emerged from the growing need to streamline the time-consuming process of academic research, where scientists spend an average of seven hours weekly searching for information and systematic reviews take 41 weeks for a five-person team. Elicit's tools aim to reduce this burden by using AI to summarize, extract, and synthesize findings from scientific papers.

While initially targeting academic researchers, the company has expanded into pharmaceutical and regulatory science applications, where evidence synthesis is critical for drug development and compliance. As of 2025, Elicit operates with a lean team, having raised an undisclosed seed round. The company faces competition from both general-purpose AI tools and specialized academic search platforms, but its focus on structured evidence extraction for high-stakes domains like medicine and toxicology differentiates its approach. Recent developments suggest a pivot toward regulatory and clinical trial applications, where traceability and auditability are non-negotiable requirements.

Track Elicit Labs and 240+ vendors.

335k+ subscribers read the daily AI & data note. One email, both newsletters. Unsubscribe anytime.

Who buys this

  • Academic researchers conducting literature reviews
  • Pharmaceutical companies analyzing clinical trial data
  • Regulatory scientists compiling evidence for compliance
  • Biotech startups scoping competitive landscapes
  • Medical writers preparing systematic reviews

Strengths and what to watch

Strengths

  • Specialized focus on scientific and medical literature, unlike general-purpose AI tools
  • Addresses a demonstrably time-consuming pain point in research workflows
  • Early mover in applying AI to systematic review processes

Watch for

  • Competition from well-funded general AI platforms adding research features
  • Accuracy challenges in high-stakes domains like medicine where errors carry risk
  • Unproven scalability beyond early adopter academic users

Key Information

Founded
2021

Frequently Asked Questions

What does Elicit Labs do?

Elicit Labs develops AI tools that automate the process of finding, summarizing, and synthesizing scientific research papers. Founded in 2021, the company focuses on reducing the time researchers spend on literature reviews, particularly in academic, pharmaceutical, and regulatory science domains.

How does Elicit Labs use AI for scientific research?

Elicit Labs uses AI to summarize, extract, and synthesize findings from scientific papers. Its tools streamline literature reviews, which traditionally take significant time, helping researchers focus on analysis rather than manual information gathering.

Who uses Elicit Labs' tools?

Elicit Labs serves academic researchers, pharmaceutical companies, regulatory scientists, biotech startups, and medical writers. These users rely on its AI tools for tasks like literature reviews, clinical trial analysis, compliance evidence compilation, and competitive landscape scoping.

What makes Elicit Labs different from other AI tools?

Elicit Labs specializes in scientific and medical literature, unlike general-purpose AI tools. Its focus on structured evidence extraction for high-stakes domains like medicine and toxicology sets it apart, addressing specific pain points in research workflows.

What are the challenges for Elicit Labs?

Elicit Labs faces competition from general AI platforms, accuracy challenges in high-stakes domains like medicine, and scalability concerns beyond academic users. Its success depends on maintaining precision and expanding into broader applications.

What are Elicit Labs' recent developments?

Elicit Labs is pivoting toward regulatory and clinical trial applications, where traceability and auditability are critical. This shift aligns with its focus on high-stakes domains like medicine, leveraging AI to streamline evidence synthesis for compliance and drug development.

Sources

  1. techcrunch.com — Company's focus on automating literature reviews
  2. edge.prnewswire.com — Context about evidence-based AI applications in medicine
  3. techcrunch.com — Industry context about AI safety challenges
  4. www.prnewswire.com — Pharmaceutical industry context where such tools are applied